A prospective study on activity of Fosfomycin on uropathogenic Escherichia coli

Introduction: Urinary tract infections (UTIs) are a major global health concern, affecting millions annually. Escherichia coli is the most common pathogen responsible for both community-acquired and hospital-associated UTIs. Fosfomycin, an older antibiotic, has gained attention for its efficacy against multidrug-resistant pathogens. This study aims to evaluate the activity of Fosfomycin against uropathogenic E.coli in Fosfomycin-naïve patients. Materials and Methods: A four-month study was conducted at Rajarajeswari Medical College and Hospital. Urine samples were collected from patients with clinical symptoms of UTIs and processed for microscopy, culture, and antibiotic sensitivity testing. E.coli isolates were tested for susceptibility to Fosfomycin using the Kirby Bauer disk diffusion method. Results: Of the 1350 samples, 480 yielded bacterial growth, with E.coli accounting for 62% of the isolates. Among the E.coli isolates, 98% were sensitive to Fosfomycin, demonstrating its high efficacy against multidrug-resistant strains. The study also showed that Fosfomycin had superior efficacy compared to other common antibiotics like nitrofurantoin and ciprofloxacin. Conclusion: Fosfomycin proves to be a highly effective treatment option for multidrug-resistant E.coli in UTIs, with a single-dose regimen, strong in vitro activity, and minimal side effects. It should be considered as a treatment of choice for complicated UTIs, also in cases of antibiotic failure or intolerance.